India’s pharmaceutical market is at a turning point. As of March 20, 2026, the patent on semaglutide—the key ingredient behind blockbuster drugs like Ozempic and Wegovy—has expired. This single development is expected to dramatically reshape how obesity and diabetes are treated in the country, opening the floodgates to cheaper, locally made alternatives. A flood of.
